Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients

NCT02012556 | Completed Phase 1

• 1 other identifier: TH9507-CTR-1015
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of the study is to determine the PK (tesamorelin) and PD (IGF-1) profiles of tesamorelin after a single 2 mg subcutaneous administration and after repeated administration once daily for 14 consecutive days. Secondary objectives include the evaluation of the safety and tolerability of tesamorelin following multiple subcutaneous injections.

Conditions

HIV

Outcome Measures

Primary Outcomes (10)

• Area under the Plasma Concentration versus Time Curve (AUC) of Tesamorelin.

  Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14.

• Peak Plasma Concentration (Cmax) of Tesamorelin.

  Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14.

• Time to Maximum Plasma Concentration (Tmax) of Tesamorelin.

  Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14.

• Apparent Elimination Half-life (T1/2 el) of Tesamorelin.

  Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14.

• Plasma Clearance (CI/F) of Tesamorelin.

  Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14.

• Apparent Volume of Distribution (Vd/F) of Tesamorelin.

  Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14.

• Insulin-like Growth Factor-1 (IGF-1) Level at Day 1.

  Day 1.

• Insulin-like Growth Factor-1 (IGF-1) Level at Day 7

  Day 7.

• Insulin-like Growth Factor-1 (IGF-1) Level at Day 13.

  Day 13.

• Insulin-like Growth Factor-1 (IGF-1) Level at Day 14.

  Day 14.

Secondary Outcomes (1)

• Number of Subjects with Adverse Events as a Measure of Safety and Tolerability

  14 days

Study Arms (1)

Tesamorelin

EXPERIMENTAL

Drug: Tesamorelin

Interventions

Tesamorelin DRUG

Also known as: Egrifta

Tesamorelin

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, smoker or non-smoker, ≥18 and ≤65 years of age.
• HIV-positive with CD4 cell counts \>100 cells/mm3 and viral load \<10 000 copies/mL.
• On stable antiretroviral therapy (ART) regimen for at least 8 weeks prior to the first study drug administration.
• Body mass index (BMI) ≥ 20.0 kg/m2.

You may not qualify if:

• Opportunistic infection or HIV-related disease within 3 months prior to study drug administration.
• History of malignancy of any organ or tissue (with the exception of basal cell carcinoma of the skin, in situ carcinoma of the cervix and stable Kaposi not having required treatment for the past 6 months).
• For male subjects, suspicion of prostate cancer.
• For female subjects, history of breast cancer or strong family history (first degree relative) of breast cancer.
• Known hypopituitarism, history of pituitary tumor/surgery, head irradiation or severe head trauma that had affected the somatotropic axis.
• Use of any experimental or marketed GH or GRF/GHRH products, GH secretagogues, IGF-1, or insulin-like growth factor binding protein-3 (IGFBP-3) within 6 months prior to study drug administration and throughout the study.
• Positive pregnancy test at screening.

Sponsors & Collaborators

• Theratechnologies: lead

Study Sites (1)

Anapharm Montreal

Montreal, Quebec, H3X 2H9, Canada

Location

MeSH Terms

Interventions

tesamorelin

Study Officials

• Richard Larouche, MD

  Anapharm

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 26, 2013
• First Posted: December 16, 2013
• Study Start: May 1, 2008
• Primary Completion: July 1, 2008
• Study Completion: July 1, 2008
• Last Updated: December 16, 2013

Record last verified: 2013-12

Locations

CA (1)